mobic and Urethral-Obstruction

Urethral obstruction (UO) is a common complication of feline idiopathic cystitis (FIC). Robust treatment recommendations to prevent its recurrence are scarce.. To evaluate meloxicam treatment for prevention of clinical recrudescence in male cats with obstructive FIC.. Fifty-one client-owned cats.. Prospective, randomized clinical trial. Every male cat with FIC-associated UO was deemed eligible for the study and was recruited during hospitalization. After discharge, cats were treated with phenoxybenzamine and alprazolam for 2 weeks, with (24 cats) or without (27 cats) low-dose meloxicam (0.025 mg/kg/day PO) and monitored for 6 months.. Cumulative number (%) of cats with recurrent UO at 10 days, 1-, 2-, and 6-months after discharge was 1 (2%), 2 (4%), 4 (8%), and 8 (16%), respectively. Overall, 12 (24%) cats experienced signs of recurrent FIC within 6 months, with (8 cats) or without (4 cats) concurrent UO. No difference in the cumulative incidence of UO within 6 months was detected with addition of meloxicam (odds ratio [95% confidence interval], 0.63 [0.13-2.97]; P = .70). All cats were alive at 6 months.. No clinical benefit was detected with the addition of low-dose meloxicam to phenoxybenzamine and alprazolam treatment for 2 weeks after discharge. Nevertheless, this study was underpowered to identify potential differences, and its findings must be corroborated in larger studies.

Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cat Diseases; Cats; Clinical Protocols; Cystitis; Hypnotics and Sedatives; Male; Meloxicam; Phenoxybenzamine; Prospective Studies; Recurrence; Urethral Obstruction

Objectives The aim of the study was to investigate the effect of the non-steroidal anti-inflammatory drug meloxicam on the clinical course of obstructive idiopathic cystitis in cats in a placebo-controlled clinical study. Methods Thirty-seven cats with obstructive idiopathic cystitis were enrolled. Cats received supportive treatment and an indwelling transurethral catheter for 48 h. On days 0 and 1, all cats received buprenorphine 0.01 mg/kg subcutaneously every 8 h. On day 1, cats were randomly assigned to the meloxicam (n = 18) or placebo group (n = 19) and received meloxicam (0.1 mg/kg on day 1, 0.05 mg/kg on days 2-5) or placebo orally for five consecutive days. Cats were monitored by repeated physical examinations and urinalysis, and with a 5 day questionnaire filled in by the owners after discharge and a telephone interview 3 months after presentation. Parameters for evaluation of treatment success were the occurrence of recurrent urethral obstruction, results of physical examinations and questionnaires. Results Recurrent urethral obstruction occurred in 4/18 cats (22%) in the meloxicam group and 5/19 cats (26%) in the placebo group ( P = 1.000). General demeanour and pain on abdominal palpation during hospitalisation improved significantly in both groups ( P <0.001). After discharge, with regard to general demeanour, food intake and voiding behaviour, there were no significant differences within or between groups at different time points. Conclusions and relevance Orally administered meloxicam for 5 days did not influence the incidence of recurrent urethral obstruction and the recovery from clinical signs in cats with obstructive feline idiopathic cystitis. The persistence of clinical signs in most of the cats 1 week after initial presentation indicates that symptomatic treatment for a longer period of time is warranted.

Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cat Diseases; Cats; Cystitis; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Meloxicam; Ownership; Pain; Pain Measurement; Surveys and Questionnaires; Thiazines; Thiazoles; Treatment Outcome; Urethral Obstruction

To evaluate the association of treatment factors during initial urinary catheterization (IUC) of cats with recurrence of urethral obstruction at 24 hours and 30 days after catheter removal.. Retrospective case series.. 192 male cats with urethral obstruction that were treated at an emergency and specialty center from 2004 through 2010.. Data were obtained from the cats' medical records. Duration of indwelling catheterization, catheterization with a 5F versus 3.5F urinary catheter, treatment with phenoxybenzamine versus prazosin, consistent administration of pain medication, and treatment with meloxicam or antimicrobials during IUC were reviewed for association with rate of recurrent urethral obstruction (rUO).. Overall rUO rates were 10.94% (21/192 cats) at 24 hours and 23.57% (37/157 cats) at 30 days after IUC. At 24 hours and 30 days after IUC, rUO developed in 10 of 140 (7.14%) and 20 of 110 (18.18%) prazosin-treated cats, respectively, compared with 10 of 46 (21.74%) and 16 of 41 (39.02%) phenoxybenzamine-treated cats, respectively. Reobstruction developed following use of a 5F or 3.5F urinary catheter in 11 of 58 (18.97%) and 7 of 105 (6.67%) cats, respectively, through 24 hours. There was no association between rUO and duration of urinary catheterization, administration of antimicrobials or meloxicam, or consistent administration of pain medication during IUC.. At 24 hours and 30 days after IUC, rUO rates in prazosin-treated cats were significantly lower than rates in phenoxybenzamine-treated cats. Reobstruction rate at 24 hours was significantly lower when a 3.5F versus 5F urinary catheter was used.

Topics: Adrenergic alpha-1 Receptor Antagonists; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cat Diseases; Cats; Male; Meloxicam; Retrospective Studies; Secondary Prevention; Thiazines; Thiazoles; Urethral Obstruction